Despite remarkable advances in the treatment of childhood acute lymphoblastic leukemia (ALL), especially with the introduction of intensive multiagent chemotherapy, infants with this disease continue to have a poor prognosis.
Introduction
Despite remarkable advances in the treatment of childhood acute lymphoblastic leukemia (ALL), especially with the introduction of intensive multiagent chemotherapy, infants with this disease continue to have a poor prognosis. 1, 2 Their leukemic cells are characterized biologically by a lack of the early lymphocyte antigen CD10 and by 11q23
translocations/MLL gene rearrangements, the latter feature being associated with a highly distinct gene expression profile and a poor outcome in most treatment programs.
3, 4
Especially dire is the prognosis for infants with the 4;11 translocation, the vast majority of whom relapse and die of progressive disease. 5, 6 On the other hand, several groups have indicated that a good initial steroid response and 11q23 translocations other than the 4;11 translocation predict a more favorable outcome in infants with ALL. 7, 8 Recently, Pui et al. 9 reported that age under 1 year and MLL rearrangements are the most adverse risk factors in childhood ALL, underscoring the clinical significance of these two characteristics. Thus, improving the prognosis of infant ALL will likely require innovative strategies in which patients with or without MLL gene rearrangements are regarded as discrete subgroups requiring different treatment protocols.
The role of hematopoietic stem cell transplantation (HSCT) in the management of infants with ALL is still unclear, 10 primarily because only small numbers of patients with documented MLL-positive ALL have been treated with this modality in reported series. [11] [12] [13] Between 1996 and 1998, we implemented a prospective treatment protocol (MLL96) that stratified infant ALL patients according to the presence or absence of MLL gene rearrangements: infants with MLL-negative ALL were treated with standard chemotherapy only, whereas those with MLL-positive disease were given intensive chemotherapy followed by HSCT. 14 Unfortunately, the results were not satisfactory, as demonstrated by a 3-year event-free survival (EFS) rate of only 34.0% in the MLL-positive subgroup, reflecting a high
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From relapse rate during the first 6 months of chemotherapy and before HSCT. However, the outcome in patients undergoing HSCT in first remission was superior to that in patients transplanted later, suggesting an advantage from early introduction of HSCT.
Consequently, to prevent early relapse in this subgroup, we instigated treatment protocol MLL98, which specified more intensive chemotherapy and HSCT early in first remission (3-5 months postdiagnosis). Here we describe the effectiveness and toxicity of this protocol, as well as the prognostic factors that appear to discriminate between subgroups of infants with a better or worse risk of treatment failure.
Patients, materials and methods

Patients
Between November 1998 and June 2002, 54 infants less than 12 months of age at the time of diagnosis of ALL were registered with the Japan Infant Leukemia Study Group and treated on the MLL98 protocol. In a nationwide surveillance study, the incidence rate of new infant ALL cases was calculated as 20 per year (96 cases between 1997 and 2001, K. Horibe, unpublished data). Therefore, the current study included approximately 80% of all infants diagnosed with ALL in Japan over the 3.5-year enrollment period. Written informed consent was obtained from the parents of all patients at the time of enrollment, and all aspects of this investigation were approved by the appropriate institutional review boards. Prior to treatment, each patient was evaluated with respect to the characteristics of their leukemic cells, including immunophenotype, cytogenetics and MLL gene rearrangement. The diagnosis of ALL was based on >30% lymphoblasts in the bone marrow (BM), with <3% staining positively for myeloperoxidase. Central nervous system (CNS) invasion was defined as more than 5 mononuclear cells per µl of cerebrospinal fluid with obvious lymphoblasts.
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Immunophenotype, cytogenetics and detection of MLL gene rearrangements
Cell surface markers were analyzed with an EPICS-PROFILE flow cytometer (Coulter Electronics, Hialeah, FL) at our central laboratory. Surface antigens studied in this investigation were as follows: CD10, CD19 and CD20 (B-cell markers); CD2, CD3, cytoplasmic CD3, CD4, CD5, CD7 and CD8 (T-cell markers); and CD13, CD14, CD33, cMPO, CD41 and glycophorin A (myeloid-cell markers). HLA-DR and CD56 served as additional cell markers. A positive reading for each antigen was defined as reactivity by 25% or more of the leukemic cells. Cytogenetic analysis of leukemic cells was performed by a G-banding technique. The presence of MLL gene rearrangements was determined by Southern blot analysis, as described previously. 14 
Briefly, DNA extracted and digested with
BamHI and HindIII was hybridized with a cDNA probe covering the breakpoint cluster region of the MLL gene.
Treatment protocol
All infants enrolled in this study were treated according to the MLL98 protocol (Fig. 1 , Table   1 ). Each patient was assigned to a subgroup according to the presence or absence of CD10 expression at diagnosis (CD10 negativity correlates closely with MLL gene rearrangement 6 ).
The subgroup assignments were reassessed when the presence or absence of an MLL gene rearrangement was determined by Southern blot analysis. Table 1 presents the details of the protocol for infants with MLL-positive ALL.
Those with CD10-positive ALL received an induction regimen of vincristine (VCR), doxorubicin (DXR), cyclophosphamide (CPA), L-asparaginase (ASP), and dexamethasone (DEX) or prednisolone (PSL) for 4 weeks, followed by etoposide (VP-16) and cytarabine (Ara-C) for 4 days. Those with CD10-negative ALL received VCR, DXR, CPA and DEX for 2 weeks followed by VP-16 and Ara-C for 4 days. Depending on the results of Southern blot analysis, the subgroup with MLL-negative ALL was then given 2 years of standard
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From chemotherapy that included consolidation, intensification, reinduction and maintenance phases. With the exception of VCR, drug dosages were based on body surface area rather than body weight, the method employed in our previous investigation. 14 This change increased the dosage of all antileukemic drugs by 1.2-to 2-fold. Thus, total doses of drugs other than VCR were reduced by one-third in patients younger than 2 months, and by one-fourth in those 2 to 4 months of age. Patients with molecularly confirmed MLL-positive ALL received three courses of intensification chemotherapy, as described in Table 1 , and then underwent HSCT. The intent was to transplant all patients in first remission preferentially within 3-5 months postdiagnosis; however, those who relapsed before HSCT underwent the procedure at relapse or in second remission. The conditioning regimen consisted of a combination of total-body irradiation (TBI; 2 Gy, twice a day on days -7 to -5 for a total of 12 
Statistical analysis
Results
Patient characteristics
Altogether, 54 infants were enrolled in the MLL98 study. Among the 44 MLL-positive patients, 3 were positive for CD10 and therefore received induction therapy specified for patients with that marker. Each of the remaining 41 patients, all of whom were CD10-negative, received the more aggressive induction therapy described in Table 1 . These 44 patients were given three courses of intensification therapy after molecular confirmation of MLL positivity. (Table 2) . Relapse occurred before HSCT in 11 patients and later in 7 (including 1 patient who failed to respond to induction therapy). Of the 5 patients who were salvaged, 2 continued in remission after first HSCT and 3 after second HSCT.
Log-rank comparison of EFS rates by selected clinical and biologic features of the MLL-positive infants (Table 3 ) generally failed to demonstrate statistically significant relationships. However, patients with CNS invasion at diagnosis and those younger than 6 months had a significantly poorer prognosis than those without these characteristics. An especially poor outcome was noted in infants younger than 6 months who presented with WBC 100 × 10 9 /L: 3-year EFS, 9.4% vs. 55.1%, P=0.0036 (Fig. 3 ).
Of the 38 infants who underwent HSCT, 29 were in first remission and 9 in second remission or relapse (Table 4) . Eighteen in first remission were transplanted within the Table   4 ). The median time to transplantation, regardless of the source of stem cells, was 5 months.
The type of HSCT was decided upon by each participating investigator, based on the availability of suitable donors at the time of transplantation. The HLA disparities at low resolution in the patients who received UCBT were: complete match in 5, one-locus mismatch in 15 and two-loci mismatch in 6. Among those undergoing RBMT, 3 had a complete match, 2 a one-locus mismatch, and 1 a two-loci mismatch, while in the RPBSCT subgroup, both patients had a one-locus mismatch. All 4 patients receiving UBMT had a complete match.
The conditioning regimen consisted of TBI in 20 patients, BU in 16 and other agents in 2.
CSA and FK506 were used as GVHD prophylaxis in 20 and 18 patients, respectively ( Table   4 ).
The 3-year post-transplant EFS rate for all 38 patients undergoing HSCT was 54.4% Since it is possible that the patients undergoing HSCT in first remission had more favorable prognostic factors than others in the series, we compared selected clinical characteristics of these two groups. Apart from an older age at diagnosis for infants transplanted in first remission (P=0.0132), there were no significant differences in gender, WBC, time to transplantation, CNS invasion and karyotype (data not shown).
Seven patients relapsed and one had graft failure following the first HSCT (Table 4) .
After subsequent UCBT (n=2), RPBSCT (n=1) or UBMT (n=2), 3 infants undergoing UCBT or UBMT attained new complete remissions without further adverse events as of April 30,
Consequently, 3 relapsed infants, including 2 undergoing HSCT in first remission and
Toxicity
A major consideration in the treatment of ALL in infants is the significant potential for toxicity due to myeloablative chemotherapy and ionizing radiation. Two patients in our series died as a result of adenoviral infection or interstitial pneumonia during induction therapy. Fatal complications were not observed during the intensification phase of chemotherapy. 14 Most of these patients relapsed within 6 months after the initiation of chemotherapy; however, the 3-year post-transplant EFS rate for MLL-positive patients undergoing HSCT in first remission was 58.0%, suggesting a therapeutic advantage for early use of transplantation.
14 Thus, in the current study, we elected to initiate HSCT within 3-5 months postdiagnosis as a means to reduce the relapse rate in infants with MLL-positive ALL who had achieved remission. The 3-year postdiagnosis EFS rate for these patients increased to 43.6%, but the gain over our previous experience was not statistically significant. 14 Nonetheless, the relatively high 3-year post-transplant EFS rate for patients undergoing HSCT in first remission (64.4%) is encouraging and supports the working hypothesis of MLL98. Failure to produce a significant improvement over the postdiagnosis HSCT results in MLL96 can be attributed, in part, to the dismal prognosis of infants with CNS invasion or age less than 6 months, many of whom relapsed before HSCT could be attempted. Clearly, the development of more effect induction and intensification therapies for these subgroups should be a priority of future investigations.
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Marco et al. 13 performed allogeneic or autologous HSCT in 26 patients with infant leukemia, including AML. They noted that patients transplanted earlier than 4 months after remission induction had a significantly better prognosis than those undergoing the procedure at later times. Moreover, the period from remission induction to transplantation was the sole prognostic factor identified by multivariate analysis. Similarly, Leung et al. 24 studied 22
infant leukemia patients treated with HSCT, reporting that disease status at transplantation was the only prognostic factor with significant predictive strength in patients in remission.
These findings, together with our similar result by multivariate analysis, suggest that the early introduction of HSCT could rescue a proportion of patients who otherwise would relapse relatively soon after induction therapy. On the other hand, Pui et al. 9 evaluated a substantial number of childhood ALL patients presenting with 11q23 abnormalities, and concluded that HSCT was not effective in this series. In this retrospective analysis, however, the treatment method, source of donor cells and conditioning regimen varied widely among the patients.
In particular, the EFS rate for infants was too low (only 19%) to permit an accurate assessment of the effect of HSCT, in contrast to our MLL98 study, in which all MLL-positive cases were assigned to the HSCT arm.
The majority of patients in the current investigation underwent UCBT rather than UBMT, for the following reasons. First, cord blood can be obtained within 2 months from donors in Japan, whereas it usually takes 5 to 6 months to identify a suitable unrelated marrow donor through the Japan Marrow Donor Program (JMDP) and proceed to transplantation. Second, cord blood can provide sufficient numbers of donor cells for patients with a low body weight, such as infants. Third, a nationwide network of cord blood In our study, the event-free survival of patients undergoing UCBT tended to be lower than that associated with other sources of donor cells. Thus, in future studies, the induction of GVL reactions using Ubenimex or GM-CSF should be considered as a means to prevent relapse.
32, 33
Two patients who underwent UCBT following treatment with the BU-containing regimen had complications associated with graft rejection. Although the pharmacokinetics of BU in infants are unknown, the absorption and metabolism of oral BU vary widely among individual patients, 34-36 indicating a need to develop an effective BU pharmacokinetics monitoring system for younger children. 37 In addition, the incidence of VOD was higher than in previous reports on the outcome of HSCT in infants, despite the administration of ursodeoxycholic acid and heparin to most patients in this investigation. The factors contributing to this unexpectedly high frequency of VOD remain unclear, and this issue must be addressed in the future.
A major concern with the use of HSCT in infants is the possibility of late adverse sequelae, including growth impairment. Pirich et al. 12 performed allogeneic HSCT in 7 infant ALL patients using a conditioning regimen that incorporated TBI, CPA and VP-16; this protocol contributed to short stature in 3 patients, with TBI implicated as the principal risk factor.
38
TBI was also reported to be a risk factor for hypopituitarism and cataract, and these
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From toxicities were inversely correlated with age. 13, 39 We analyzed growth and development in 34 infants with ALL followed for 5 to 8 years who had been treated on MLL96 protocol, 14 which included intensive chemotherapy and HSCT administered in much the same way as in the MLL98 study. Growth (body height and body weight) was compared by analysis of variance among patients receiving chemotherapy alone (chemotherapy group, n=19), HSCT with a TBI conditioning regimen (TBI group, n=9), and HSCT with a BU conditioning regimen (BU group, n=6) at the onset of leukemia, at the time of treatment cessation, and at 1, Recently, reduced-intensity hematopoietic stem cell transplantation (RIST) using nonmyeloablative conditioning has become available for leukemia patients.
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Since the effects of HSCT are partly attributable to an antileukemic immune reaction mediated by donor lymphocytes, the aim of RIST is to promote a GVL effect, thus contributing to an improved Abbreviations: VCR, vincristine; DEX, dexamethasone; CPA, cyclophosphamide; DXR, doxorubicin; VP-16, etoposide; Ara-C, cytarabine; THP-DXR, tetrahydropyranyl doxorubicin; PSL, prednisolone; ASP, L-asparaginase; MTX, methotrexate; MIT, mitoxanthrone; TIT, triple intrathecal therapy (age <3 months: MTX, 3 mg; hydrocortisone, 10 mg; Ara-C, 6 mg, age 3 months: MTX, 6 mg; hydrocortisone, 10 mg; Ara-C, 12 mg); IV, intravenously; DIV, drip intravenously; PO, by mouth. * The dose of each drug except VCR was reduced by one-third in patients younger than 2 months, and by one-fourth in those 2 to 4 months of age. 
Duration of EFS (months) EFS rate (%)
Duration of EFS after HSCT (months) EFS rate (%)
